Shares of GH Research PLC (NASDAQ:GHRS) surged 90% following the announcement that its Phase 2b trial for GH001, an inhalable treatment for treatment-resistant depression (TRD), met its primary ...

PLC reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with ...

Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of ...

"Imvax secures $29m to support Phase IIb glioblastoma therapy trial" was originally created and published by Clinical Trials ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...

All subjects enrolled in Island Pharmaceutical’s phase 2b arm of phase 2a/b PROTECT trial of ISLA-101 in dengue fever Phase ...

GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a ...

Credit: Komsan Loonprom / Shutterstock. Imvax has received $29m in a financing round from current investors, aimed at advancing the Phase IIb trial of its autologous biologic-device combination ...

Akero Therapeutics has revealed preliminary outcomes from its Phase IIb study of EFX in individuals with compensated ...

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...